Y Intercept Hong Kong Ltd Takes Position in Intellia Therapeutics, Inc. $NTLA

Y Intercept Hong Kong Ltd acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the third quarter, according to its most recent filing with the SEC. The firm acquired 137,290 shares of the company’s stock, valued at approximately $2,371,000.

Other institutional investors have also recently made changes to their positions in the company. Grandfield & Dodd LLC grew its stake in shares of Intellia Therapeutics by 4.3% in the 3rd quarter. Grandfield & Dodd LLC now owns 50,790 shares of the company’s stock worth $877,000 after buying an additional 2,085 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Intellia Therapeutics by 74.5% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 113,438 shares of the company’s stock worth $1,959,000 after purchasing an additional 48,438 shares in the last quarter. Nwam LLC purchased a new position in shares of Intellia Therapeutics in the third quarter worth $181,000. GWN Securities Inc. bought a new stake in shares of Intellia Therapeutics in the third quarter worth about $218,000. Finally, Benjamin Edwards Inc. boosted its position in shares of Intellia Therapeutics by 2.9% during the 3rd quarter. Benjamin Edwards Inc. now owns 64,850 shares of the company’s stock valued at $1,120,000 after acquiring an additional 1,816 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Insider Activity at Intellia Therapeutics

In related news, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the sale, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 53,051 shares of company stock worth $488,600. Company insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the topic of several analyst reports. Wedbush cut their price target on shares of Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Oppenheimer set a $27.00 price objective on shares of Intellia Therapeutics in a research note on Friday, November 7th. Wells Fargo & Company dropped their price objective on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. JMP Securities reduced their price target on Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating on the stock in a research report on Tuesday, October 28th. Finally, Evercore ISI set a $8.00 target price on shares of Intellia Therapeutics and gave the stock an “in-line” rating in a research report on Tuesday, November 11th. Nine investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $17.19.

Intellia Therapeutics Stock Down 4.5%

Shares of Intellia Therapeutics stock traded down $0.66 during trading hours on Wednesday, reaching $14.17. 620,849 shares of the company’s stock were exchanged, compared to its average volume of 6,774,276. The business has a fifty day moving average of $10.11 and a two-hundred day moving average of $12.93. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.25. The company has a market capitalization of $1.64 billion, a P/E ratio of -3.33 and a beta of 2.05.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.10. The firm had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. Intellia Therapeutics’s revenue was up 51.6% compared to the same quarter last year. During the same period last year, the business earned ($1.34) earnings per share. As a group, research analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.